Comparative morphology of the first zoea of twelve brachyuran species (Crustacea: Decapoda) from the Amazon region

The laboratory-hatched first zoeal stage of twelve brachyuran species collected in the estuarine area of the Caeté River in the Amazonian region are described and illustrated in the present study: P. americanus Saussure, 1857, Eurytium limosum (Say, 1818), Sesarma curacaoense De Man, 1892, S. rectum Randall, 1840, Armases rubripes (Rathbun, 1897), Aratus pisonii (H. Milne Edwards, 1837), Ocypode quadrata (Fabricius, 1787), Uca rapax (Smith, 1870), U. maracoani (Latreille, 1802), U. thayeri Rathbun, 1900, Ucides cordatus (Linnaeus, 1763) and Pachygrapsus gracilis (Saussure, 1858). Through intraspecific comparisons of the respective larval stage, an identification key was generated and provided. Most of the studied species presented morphological differences (e.g. type and presence or absence of setae) when compared to the same species previously described in the literature.

Redescription of Pseudopomyzella flava Hennig (Diptera: Cypselosomatidae) and the first record from Brazil

Cypselosomatidae é composta por Cypselosomatinae e Pseudopomyzinae, incluindo 11 gêneros atuais. O gênero Rhinopomyzella Hennig (Pseudopomyzinae) é o único registrado para o Brasil, representado por duas espécies de Santa Catarina. O gênero Pseudopomyzella Hennig compreende uma única espécie, Pseudopomyzella flava Hennig, encontrada no Peru e Equador. Neste estudo, P. flava é registrada pela primeira vez para o Brasil (Pará) e a espécie é redescrita a partir dos espécimes coletados.

Oral live attenuated human rotavirus vaccine (RotarixTM) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children

In a large Phase III trial conducted in 10 Latin American countries, the safety and efficacy of the live attenuated monovalent rotavirus vaccine RIX4414 was evaluated in 15,183 healthy infants followed up during the first two years of life. Belém was the only site in Brazil included in this multicentre trial. The study in Belém included a subset of 653 infants who were followed up until 24 months of age for protection against severe rotavirus gastroenteritis. These subjects were randomly assigned in a 1:1 ratio to receive two doses of vaccine (n = 328) or two doses of placebo (n = 325) at approximately two and four months of age. Of the 653 enrolled infants, 23 dropped out during the study period. For the combined two-year period, the efficacy of RIX4414 was 72.3% [95% confidence interval (CI) 37.5-89.1%] against severe rotavirus-related gastroenteritis, reaching a protection rate of 81.8% (95% CI 36.4-96.6%) against circulating wild-type G9 rotavirus strains. It is concluded that two doses of RIX4414 are highly efficacious against severe rotavirus gastroenteritis in Belém during the first two years of life and provide high protection against the worldwide emergence and spread of G9P[8] strains.